海思科 (002653.SZ) Latest Company News

Aug 26, 2026, 18:02 UTC
Haisco licensed its preclinical immunology asset to Sentivera in a deal valued at more than $1.5 billion.
Source:
- pharmexec.com
Aug 26, 2026, 10:27 UTC
Haisco Pharmaceutical proposed a cash dividend of 5.26 yuan per 10 shares (tax included) to all shareholders, based on a base of 1.141 billion shares.
Source:
- finance.sina.cn
Aug 26, 2026, 10:27 UTC
Haisco Pharmaceutical announced its 2026 first-half results: revenue of 3.096 billion yuan, up 54.71% year-on-year; net profit attributable to shareholders of 851 million yuan, up 426.98% year-on-year.
Source:
- finance.sina.cn
Aug 12, 2026, 07:40 UTC
Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule drug HSK60002, intended for inflammatory diseases.
Source:
- finance.sina.cn
Aug 11, 2026, 11:03 UTC
Haisco Pharmaceutical Group shareholder Fan Xiulian pledged 29 million shares on August 10, 2026, as collateral for a loan, with the pledge maturing on August 9, 2029.
Source:
- finance.sina.cn
Aug 6, 2026, 08:07 UTC
Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule analgesic drug HSK51155, intended for migraine treatment.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 23, 2026, 03:47 UTC
Haisco announced that its Class 1 innovative drug, Succinate Sipukepan Tablets, received marketing approval from China's National Medical Products Administration for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitor therapy.
Source:
- finance.sina.cn
Jul 23, 2026, 02:32 UTC
China's National Medical Products Administration approved two innovative drugs through priority review: Takeda's ORZEYFUL for narcolepsy and Haisco Pharmaceutical's suplatast tosilate for PNH.
Source:
- finance.sina.cn
Jun 22, 2026, 11:48 UTC
Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.
Source:

002653.SZ

Haisco licensed its preclinical immunology asset to Sentivera in a deal valued at more than $1.5 billion.

Haisco Pharmaceutical proposed a cash dividend of 5.26 yuan per 10 shares (tax included) to all shareholders, based on a base of 1.141 billion shares.

Haisco Pharmaceutical announced its 2026 first-half results: revenue of 3.096 billion yuan, up 54.71% year-on-year; net profit attributable to shareholders of 851 million yuan, up 426.98% year-on-year.

Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule drug HSK60002, intended for inflammatory diseases.

Haisco Pharmaceutical Group shareholder Fan Xiulian pledged 29 million shares on August 10, 2026, as collateral for a loan, with the pledge maturing on August 9, 2029.

Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule analgesic drug HSK51155, intended for migraine treatment.

Haisco announced that its Class 1 innovative drug, Succinate Sipukepan Tablets, received marketing approval from China's National Medical Products Administration for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitor therapy.

China's National Medical Products Administration approved two innovative drugs through priority review: Takeda's ORZEYFUL for narcolepsy and Haisco Pharmaceutical's suplatast tosilate for PNH.

Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.